{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,2]],"date-time":"2022-04-02T10:32:24Z","timestamp":1648895544788},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2012,12,1]],"date-time":"2012-12-01T00:00:00Z","timestamp":1354320000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Huazhong Univ. Sci. Technol. [Med. Sci.]"],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.1007\/s11596-012-1054-y","type":"journal-article","created":{"date-parts":[[2012,12,27]],"date-time":"2012-12-27T12:22:44Z","timestamp":1356610964000},"page":"893-898","source":"Crossref","is-referenced-by-count":0,"title":["Preliminary evaluation of safety of conditionally replication adenovirus M4"],"prefix":"10.1007","volume":"32","author":[{"given":"Caihong","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haiyan","family":"Fang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yumei","family":"Rao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peng","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ding","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qinglei","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,12,28]]},"reference":[{"issue":"11","key":"1054_CR1","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1089\/hum.2004.15.1034","volume":"15","author":"H. Mizuguchi","year":"2004","unstructured":"Mizuguchi H, Hayakawa T. Targeted adenovirus vectors. Hum Gene Ther, 2004,15(11):1034\u20131044","journal-title":"Hum Gene Ther"},{"issue":"22","key":"1054_CR2","first-page":"6359","volume":"60","author":"J. Emunaitis","year":"2000","unstructured":"Emunaitis J, Ganly I, Khuri F, et al. Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial. Cancer Res, 2000,60(22):6359\u20136366","journal-title":"Cancer Res"},{"issue":"20","key":"1054_CR3","first-page":"7464","volume":"61","author":"T.L. DeWeese","year":"2001","unstructured":"DeWeese TL, van der Poel H, Li S, et al. A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy. Cancer Res, 2001,61(20):7464\u20137472","journal-title":"Cancer Res"},{"issue":"21","key":"1054_CR4","first-page":"7497","volume":"63","author":"S.O. Freytag","year":"2003","unstructured":"Freytag SO, Stricker H, Pegg J, et al. Phase I study of replication-competent adenovirus-mediated double- suicide gene therapy in combination with conventional- dose three-dimensional conformal radiation therapy for the treatment of newly diagnosed, intermediate- to high-risk prostate cancer. Cancer Res, 2003,63(21):7497\u20137506","journal-title":"Cancer Res"},{"issue":"4","key":"1054_CR5","first-page":"389","volume":"196","author":"J.G. Page","year":"2007","unstructured":"Page JG, Tian B, Schweikart K, et al. Identifying the safety profile of a novel infectivity-enhanced conditionally replicative adenovirus, Ad5-delta24-RGD, in anticipation of a phase I trial for recurrent ovarian cancer. Am J Obstet Gynecol, 2007,196(4):389 e1\u20139; discussion 389 e9\u201310","journal-title":"Am J Obstet Gynecol"},{"issue":"12","key":"1054_CR6","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1093\/carcin\/bgp249","volume":"30","author":"Z. Han","year":"2009","unstructured":"Han Z, Hong Z, Chen C, et al. A novel oncolytic adenovirus selectively silences the expression of tumor-associated STAT3 and exhibits potent antitumoral activity. Carcinogenesis, 2009,30(12):2014\u20132022","journal-title":"Carcinogenesis"},{"issue":"19","key":"1054_CR7","doi-asserted-by":"crossref","first-page":"5847","DOI":"10.1158\/1078-0432.CCR-07-0499","volume":"13","author":"N. Li","year":"2007","unstructured":"Li N, Zhou J, Weng D, et al. Adjuvant adenovirus-mediated delivery of herpes simplex virus thymidine kinase administration improves outcome of liver transplantation in patients with advanced hepatocellular carcinoma. Clin Cancer Res, 2007,13(19):5847\u20135854","journal-title":"Clin Cancer Res"},{"issue":"6","key":"1054_CR8","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1586\/erv.09.29","volume":"8","author":"E.E. Thacker","year":"2009","unstructured":"Thacker EE, Timares L, Matthews QL. Strategies to overcome host immunity to adenovirus vectors in vaccine development. Expert Rev Vaccines, 2009,8(6):761\u201377","journal-title":"Expert Rev Vaccines"},{"issue":"5","key":"1054_CR9","first-page":"423","volume":"4","author":"D.H. Palmer","year":"2002","unstructured":"Palmer DH, Mautner V, Kerr DJ. Clinical experience with adenovirus in cancer therapy. Curr Opin Mol Ther, 2002,4(5):423\u2013434","journal-title":"Curr Opin Mol Ther"},{"issue":"5","key":"1054_CR10","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/sj.gt.3302347","volume":"12","author":"A.N. Varnavski","year":"2005","unstructured":"Varnavski AN, Calcedo R, Bove M, et al. Evaluation of toxicity from high-dose systemic administration of recombinant adenovirus vector in vector-naive and preimmunized mice. Gene Ther, 2005,12(5):427\u2013436","journal-title":"Gene Ther"},{"issue":"2","key":"1054_CR11","first-page":"693","volume":"9","author":"D. Makower","year":"2003","unstructured":"Makower D, Rozenblit A, Kaufman H, et al. Phase II clinical trial of intralesional administration of the oncolytic adenovirus ONYX-015 in patients with hepatobiliary tumors with correlative p53 studies. Clin Cancer Res, 2003,9(2):693\u2013702","journal-title":"Clin Cancer Res"},{"issue":"24","key":"1054_CR12","doi-asserted-by":"crossref","first-page":"3634","DOI":"10.3748\/wjg.v10.i24.3634","volume":"10","author":"W. Lu","year":"2004","unstructured":"Lu W, Zheng S, Li XF, et al. Intra-tumor injection of H101, a recombinant adenovirus, in combination with chemotherapy in patients with advanced cancers: a pilot phase II clinical trial. World J Gastroenterol, 2004,10(24): 3634\u20133638","journal-title":"World J Gastroenterol"},{"issue":"1","key":"1054_CR13","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1093\/toxsci\/kfn168","volume":"106","author":"C. Su","year":"2008","unstructured":"Su C, Cao H, Tan S, et al. Toxicology profiles of a novel p53-armed replication-competent oncolytic adenovirus in rodents, felids, and nonhuman primates. Toxicol Sci, 2008,106(1):242\u2013250","journal-title":"Toxicol Sci"},{"issue":"1","key":"1054_CR14","first-page":"23","volume":"17","author":"C. Page","year":"2000","unstructured":"Page C, Huang M, Jin X, et al. Elevated phosphorylation of AKT and STAT3 in prostate, breast, and cervical cancer cells. Int J Oncol, 2000,17(1):23\u201328","journal-title":"Int J Oncol"},{"issue":"22","key":"1054_CR15","first-page":"6659","volume":"62","author":"L.B. Mora","year":"2002","unstructured":"Mora LB, Buettner R, Seigne J, et al. Constitutive activation of STAT3 in human prostate tumors and cell lines: direct inhibition of STAT3 signaling induces apoptosis of prostate cancer cells. Cancer Res, 2002, 62(22):6659\u20136666","journal-title":"Cancer Res"},{"issue":"8","key":"1054_CR16","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1136\/jcp.2004.023416","volume":"58","author":"T. Kusaba","year":"2005","unstructured":"Kusaba T, Nakayama T, Yamazumi K, et al. Expression of p-STAT3 in human colorectal adenocarcinoma and adenoma; correlation with clinicopathological factors. J Clin Pathol, 2005,58(8):833\u2013838","journal-title":"J Clin Pathol"},{"issue":"11","key":"1054_CR17","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1002\/cncr.22293","volume":"107","author":"D.G. Rosen","year":"2006","unstructured":"Rosen DG, Mercado-Uribe I, Yang G, et al. The role of constitutively active signal transducer and activator of transcription 3 in ovarian tumorigenesis and prognosis. Cancer, 2006,107(11):2730\u20132740","journal-title":"Cancer"},{"issue":"5","key":"1054_CR18","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1517\/14728222.8.5.409","volume":"8","author":"J. Turkson","year":"2004","unstructured":"Turkson J. STAT proteins as novel targets for cancer drug discovery. Expert Opin Ther Targets, 2004,8(5):409\u2013422","journal-title":"Expert Opin Ther Targets"},{"issue":"56","key":"1054_CR19","doi-asserted-by":"crossref","first-page":"6613","DOI":"10.1038\/sj.onc.1204086","volume":"19","author":"J. Turkson","year":"2000","unstructured":"Turkson J, Jove R. STAT proteins: novel molecular targets for cancer drug discovery. Oncogene, 2000,19(56): 6613\u20136626","journal-title":"Oncogene"},{"issue":"2","key":"1054_CR20","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/nrc1275","volume":"4","author":"H. Yu","year":"2004","unstructured":"Yu H, Jove R. The STATs of cancer-new molecular targets come of age. Nat Rev Cancer, 2004,4(2):97\u2013105","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"1054_CR21","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/cr.2008.18","volume":"18","author":"K. Zaid Siddiquee Al","year":"2008","unstructured":"Al Zaid Siddiquee K, Turkson J. STAT3 as a target for inducing apoptosis in solid and hematological tumors. Cell Res, 2008,18(2):254\u2013267","journal-title":"Cell Res"},{"issue":"6","key":"1054_CR22","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1182\/blood-2009-10-246363","volume":"115","author":"F.P. Santos","year":"2010","unstructured":"Santos FP, Kantarjian HM, Jain N, et al. Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera\/essential thrombocythemia myelofibrosis. Blood, 2010,115(6): 1131\u20131136","journal-title":"Blood"},{"issue":"12","key":"1054_CR23","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJMoa1002028","volume":"363","author":"S. Verstovsek","year":"2010","unstructured":"Verstovsek S, Kantarjian H, Mesa RA, et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med, 2010,363(12):1117\u20131127","journal-title":"N Engl J Med"},{"issue":"4","key":"1054_CR24","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1002\/jcb.22328","volume":"108","author":"A.K. Zaiss","year":"2009","unstructured":"Zaiss AK, Machado HB, Herschman HR. The influence of innate and pre-existing immunity on adenovirus therapy. J Cell Biochem, 2009,108(4):778\u2013790","journal-title":"J Cell Biochem"}],"container-title":["Journal of Huazhong University of Science and Technology [Medical Sciences]"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11596-012-1054-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11596-012-1054-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11596-012-1054-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,7]],"date-time":"2019-07-07T16:45:47Z","timestamp":1562517947000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11596-012-1054-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12]]},"references-count":24,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["1054"],"URL":"https:\/\/doi.org\/10.1007\/s11596-012-1054-y","relation":{},"ISSN":["1672-0733","1993-1352"],"issn-type":[{"value":"1672-0733","type":"print"},{"value":"1993-1352","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,12]]}}}